Insider Transactions Reported by 20 Insiders of Celldex Therapeutics, Inc.

Symbol: CLDX on Nasdaq
Location: Hampton, NJ

Quick Takeaways

CLDX - Celldex Therapeutics, Inc. has 20 insiders with reported activity on this page.
Net insider value flow over the last year: -$1,323,482.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: ; sell value: $1,323,482.
Net share flow: -54,235.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$1,323,482.

Buys

Shares: 0

Insiders: 0

Sells

$1,323,482

Shares: 54,235

Insiders: 2

Net

-$1,323,482

Shares: -54,235

Insiders: -2

Window (months)	Sell shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	53,464	$0	$1,304,386	-$1,304,386
6-9	771	$0	$19,096	-$19,096
9-12	0	$0	$0	$0

Celldex Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Anthony S. Marucci	PRESIDENT & CEO, Director	$1,080,417			Filing P/S	05 Jun 2025
Freddy A. Jimenez	Svp & General Counsel	$896,009	-$140,306	-14%	Filing P/S	04 Dec 2025
Diane C. Young	Svp, Chief Medical Officer	$600,021			Mixed	05 Jun 2025
Richard M. Wright	Former Officer	$500,002	-$1,183,177	-70%	Filing P/S	13 Nov 2025
Samuel Bates Martin	Svp And Cfo	$341,937			Mixed	02 Jan 2026
Elizabeth Crowley	Sr. Vp & Cpdo	$316,369			Filing P/S	05 Jun 2025
James J. Marino	Director	$59,111			Mixed	05 Jun 2025
Ph.D. Ronald A. Pepin	Sr. Vp & Cbo	$55,869			Mixed	15 Dec 2025
Margo Heath-Chiozzi	Svp Of Regulatory Affairs				Mixed	05 Jun 2025
Sarah Cavanaugh	Svp Of Corp Affairs & Admin.				Mixed	05 Jun 2025
Harry H. Penner Jr.	Director				Mixed	05 Jun 2025
Garry Arthur Neil	Director				Mixed	05 Jun 2025
Teri L. Lawver	SVP & Chief Commercial Officer				Mixed	10 Nov 2025
Karen L. Shoos	Director				Mixed	13 Jun 2024
Tibor Keler	Executive Vp & Cso				Mixed	05 Jun 2025
Cheryl Cohen	Director				Mixed	05 Jun 2025
Rita Jain	Director				Mixed	05 Jun 2025
Keith L. Brownlie	Director				Mixed	05 Jun 2025
Herbert J. Conrad	Director				Mixed	05 Jun 2025
Denice Torres	Director				Mixed	05 Jun 2025

Top shareholders of Celldex Therapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
WELLINGTON MANAGEMENT GROUP LLP	13F 13D/G	Company	12% from 13D/G	8,079,608	$219,442,154	—	31 Dec 2025	13F 13D/G
Kynam Capital Management, LP	13F 13D/G	Company	9.8% from 13D/G	5,943,180	$161,416,769	—	31 Dec 2025	13F 13D/G
BlackRock, Inc.	13F 13D/G	Company	7.3% from 13D/G	5,451,815	$148,071,294	—	31 Dec 2025	13F 13D/G
FMR LLC	13F 13D/G	Company	7.3% from 13D/G	4,907,469	$133,286,863	—	31 Dec 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	6%	4,027,407	$109,384,374	—	31 Dec 2025	13F
Bellevue Group AG	13F 13D/G	Company	5.4% from 13D/G	3,617,669	$98,255,890	—	31 Dec 2025	13F 13D/G
STATE STREET CORP	13D/G 13F	STATE STREET CORPORATION · Company	5.1%	3,397,713	$92,281,885	$0	31 Dec 2025	13D/G 13F
Commodore Capital LP	13D/G 13F	Company	4.6%	3,028,335	$78,343,026	-$8,321,474	30 Sep 2025	13D/G 13F
PRICE T ROWE ASSOCIATES INC /MD/	13D/G 13F	T. Rowe Price Associates, Inc. · Company	3.6%	2,382,701	$61,640,475	-$30,382,633	30 Sep 2025	13D/G 13F
Deep Track Capital, LP	13F	Company	2.8%	1,900,738	$51,624,044	—	31 Dec 2025	13F
BRAIDWELL LP	13F	Company	2.7%	1,858,109	$50,466,240	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F 13D/G	Company	2.6% from 13D/G	1,758,357	$47,756,976	—	31 Dec 2025	13F 13D/G
EVENTIDE ASSET MANAGEMENT, LLC	13F 13D/G	Company	2% from 13D/G	1,642,559	$44,607,415	—	31 Dec 2025	13F 13D/G
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	2.4%	1,627,529	$44,211,330	—	31 Dec 2025	13F
Eversept Partners, LP	13F	Company	2.1%	1,434,725	$38,967,131	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.8%	1,212,705	$32,937,068	—	31 Dec 2025	13F
Novo Holdings A/S	13F	Company	1.8%	1,200,000	$32,592,000	—	31 Dec 2025	13F
Vestal Point Capital, LP	13F	Company	1.7%	1,165,000	$31,641,400	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	1.6%	1,068,131	$29,010,438	—	31 Dec 2025	13F
Polar Capital Holdings Plc	13F	Company	1.5%	1,008,163	$27,381,707	—	31 Dec 2025	13F
Pictet Asset Management Holding SA	13F	Company	1.4%	968,616	$26,307,611	—	31 Dec 2025	13F
Fisher Asset Management, LLC	13F	Company	1.4%	937,158	$25,453,210	—	31 Dec 2025	13F
Elmind Capital, LP	13F	Company	1.3%	865,000	$23,493,400	—	31 Dec 2025	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	1.3%	855,226	$23,227,976	—	31 Dec 2025	13F
Rock Springs Capital Management LP	13F	Company	1%	692,538	$18,809,332	—	31 Dec 2025	13F
BAKER BROS. ADVISORS LP	13F	Company	0.98%	665,370	$18,071,449	—	31 Dec 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.96%	651,716	$17,699,718	—	31 Dec 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.96%	646,767	$17,566,192	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.81%	550,729	$14,957,800	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.81%	549,998	$14,937,946	—	31 Dec 2025	13F
SEGALL BRYANT & HAMILL, LLC	13F	Company	0.76%	514,531	$13,974,662	—	31 Dec 2025	13F
Woodline Partners LP	13F	Company	0.74%	500,127	$13,583,449	—	31 Dec 2025	13F
5AM Venture Management, LLC	13F	Company	0.74%	497,270	$13,505,853	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.61%	414,888	$11,268,359	—	31 Dec 2025	13F
Affinity Asset Advisors, LLC	13F	Company	0.52%	350,000	$9,506,000	—	31 Dec 2025	13F
Logos Global Management LP	13F	Company	0.52%	350,000	$9,506,000	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.48%	326,462	$8,866,707	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.42%	285,535	$7,755,155	—	31 Dec 2025	13F
Redmile Group, LLC	13F	Company	0.42%	283,308	$7,694,645	—	31 Dec 2025	13F
Tetragon Partners GP Ltd	13F	Company	0.36%	243,800	$6,621,608	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.36%	240,594	$6,534,533	—	31 Dec 2025	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.35%	239,764	$6,511,990	—	31 Dec 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.34%	230,662	$6,264,780	—	31 Dec 2025	13F
Corient Private Wealth LLC	13F	Company	0.35%	234,698	$6,209,889	—	31 Dec 2025	13F
Nuveen, LLC	13F	Company	0.3%	200,696	$5,450,904	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.29%	194,552	$5,284,020	—	31 Dec 2025	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.28%	191,074	$5,189,570	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.26%	173,677	$4,717,067	—	31 Dec 2025	13F
Mirador Capital Partners LP	13F	Company	0.25%	170,659	$4,635,098	—	31 Dec 2025	13F
GordonMD Global Investments LP	13F	Company	0.25%	170,307	$4,625,538	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for Celldex Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Samuel Bates Martin	CLDX	Common Stock	Options Exercise	17.1%			4,817	32,942	02 Jan 2026	Direct
Samuel Bates Martin	CLDX	Incentive Stock Option (Right to Buy)	Options Exercise	-7.57%			-4,817	58,815	02 Jan 2026	Direct
Ph.D. Ronald A. Pepin	CLDX	Common Stock	Options Exercise	2530.5%			19,333	20,097	15 Dec 2025	Direct
Ph.D. Ronald A. Pepin	CLDX	Incentive Stock Option (right to buy)	Options Exercise	-100%			-19,333	0	15 Dec 2025	Direct
Freddy A. Jimenez	CLDX	Common Stock	Sale	-11.9%	$121,210	$29.10	-4,166	30,796	04 Dec 2025	Direct
Richard M. Wright	CLDX	Common Stock	Sale	-70.3%	$1,183,177	$24.00	-49,298	20,833	13 Nov 2025	Direct
Richard M. Wright	CLDX	Common Stock	Options Exercise	236.6%			49,298	70,131	13 Nov 2025	Direct
Richard M. Wright	CLDX	Incentive Stock Option	Options Exercise	-100%			-49,298	0	13 Nov 2025	Direct
Teri L. Lawver	CLDX	ISO (right to buy)	Award				100,000	100,000	10 Nov 2025	Direct
Freddy A. Jimenez	CLDX	Common Stock	Sale	-2.16%	$19,096	$24.77	-771	34,962	13 Aug 2025	Direct
Sarah Cavanaugh	CLDX	Incentive Stock Option (right to buy)	Award				78,000	78,000	05 Jun 2025	Direct
Elizabeth Crowley	CLDX	Incentive Stock Option (right to buy)	Award				85,000	85,000	05 Jun 2025	Direct
Margo Heath-Chiozzi	CLDX	Incentive Stock Option (right to buy)	Award				82,000	82,000	05 Jun 2025	Direct
Freddy A. Jimenez	CLDX	Incentive Stock Option (right to buy)	Award				75,000	75,000	05 Jun 2025	Direct
Samuel Bates Martin	CLDX	Incentive Stock Option (right to buy)	Award				81,000	81,000	05 Jun 2025	Direct
Ph.D. Ronald A. Pepin	CLDX	Incentive Stock Option (right to buy)	Award				20,000	20,000	05 Jun 2025	Direct
Diane C. Young	CLDX	Incentive Stock Option (right to buy)	Award				72,000	72,000	05 Jun 2025	Direct
Tibor Keler	CLDX	Incentive Stock Option (right to buy)	Award				93,000	93,000	05 Jun 2025	Direct
Anthony S. Marucci	CLDX	Incentive Stock Option (right to buy)	Award				300,000	300,000	05 Jun 2025	Direct
Denice Torres	CLDX	Non-Qualified Stock Option (right to buy)	Award				33,000	33,000	05 Jun 2025	Direct
Rita Jain	CLDX	Non-Qualified Stock Option (right to buy)	Award				16,500	16,500	05 Jun 2025	Direct
Garry Arthur Neil	CLDX	Non-Qualified Stock Option (right to buy)	Award				16,500	16,500	05 Jun 2025	Direct
Harry H. Penner Jr.	CLDX	Non-Qualified Stock Option (right to buy)	Award				16,500	16,500	05 Jun 2025	Direct
Herbert J. Conrad	CLDX	Non-Qualified Stock Option (right to buy)	Award				16,500	16,500	05 Jun 2025	Direct
James J. Marino	CLDX	Non-Qualified Stock Option (right to buy)	Award				16,500	16,500	05 Jun 2025	Direct
Keith L. Brownlie	CLDX	Non-Qualified Stock Option (right to buy)	Award				16,500	16,500	05 Jun 2025	Direct
Cheryl L. Cohen	CLDX	Non-Qualified Stock Option (right to buy)	Award				16,500	16,500	05 Jun 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.